




MYLAN®

## The History of Mylan

### The 1960s

#### Mylan During Its First Decade

Mylan Pharmaceuticals becomes “Mylan” Pharmaceuticals—one of many changes the company undergoes as it begins to gain a foothold in the pharmaceutical industry. Mylan moves twice to larger quarters and expands its position from distributor only to pharmaceutical manufacturer. Production increases steadily, and a major brand-name pharmaceutical company becomes the first among its peers to purchase products manufactured by Mylan.



- ◆ **1963:** Mylan relocates its operations to Princeton, West Virginia.



- ◆ **1965:** Time for another relocation! Mylan moves again to its present location in Morgantown, West Virginia.



- ◆ **1966:** Mylan receives approval to begin manufacturing penicillin G tablets.



- ◆ **1969:** The first major brand-name pharmaceutical company purchases finished goods from Mylan.

### The 1970s

#### With a Growing Product Offering and Client List, Mylan Goes Public

As the Mylan product line and number of major customers continue to increase, the company relinquishes its private status and becomes a publicly owned company with new management—which leads to Mike Puskar’s departure. Ensuing years bring financial difficulties. Mike Puskar agrees to return as President and is joined by Roy McKnight, who takes the reins as Chief Executive Officer. Their guidance and innovation jump-start the company, leading to a remarkable recovery.



- ◆ **1973:** The first shares of stock are traded February 15 on the Over-The-Counter (OTC) Market, and Mylan goes from being a privately owned to a publicly traded company under the ticker symbol MYLN.



- ◆ **1976:** The “dynamic duo” of Mike Puskar and Roy McKnight takes over on May 13. Mylan experiences unprecedented growth under their leadership, and the company soon becomes eligible to be traded on the NASDAQ.



MYLAN®

## The History of Mylan

### The 1980s

#### Mylan Develops Its First Drug, Expands Operations, and Exposes Corruption

The 80's was a booming time for the economy and for Mylan. The company begins to produce products under the Mylan label. With the development of the anti-hypertensive Maxzide®, Mylan becomes the first generic pharmaceutical manufacturer to patent a new drug. The company celebrates its 25-year anniversary and becomes a member of The New York Stock Exchange. Looking ahead, Mylan, in a joint venture, purchases Somerset Pharmaceuticals, an important strategic move. As the decade draws to a close, the team of Mike Puskar and Roy McKnight exposes corruption within the Food and Drug Administration (FDA) and a number of generic companies. The resulting investigation leads to judicial action that fortifies the generic pharmaceutical industry.



- ◆ **1980:** Mylan discontinues private-label manufacturing in favor of its own line of “Mylan-labeled” products. This decision becomes the catalyst for continued success.



- ◆ **1984:** Mylan receives approval of its first proprietary product—Maxzide, an anti-hypertensive developed by Mylan. It is the first generic manufacturer to patent a new drug.



- ◆ **1986:** On April 14, Mylan becomes a member of the “Big Board”—The New York Stock Exchange—and its symbol becomes MYL.



- ◆ **1987:** Mylan opens a second manufacturing facility in Caguas, Puerto Rico.

- ◆ **1988:** In June, Mylan opens its first distribution center in Greensboro, North Carolina.



MYLAN®

## The History of Mylan

### The 1990s

#### **Mylan Acquires Innovative Companies, Names Mike Puskar Chairman, and Gains Numerous Product Approvals**

During the century's last decade, Mylan acquires a number of companies to establish an even stronger presence in the pharmaceutical industry. These include Dow B. Hickam, Inc., known for its skilled sales force, Bertek, Inc., known for transdermal drug delivery and Penederm Inc., recognized in dermatology—all three act as a springboard for the creation of Bertek Pharmaceuticals Inc. In addition, UDL Laboratories, Inc., a leader in unit-dose packaging, becomes part of the Mylan Family of Companies.

Mylan receives approval for the orphan drug cysteamine bitartrate, which helps to control a rare genetic disorder called cystinosis; the product is marketed as Cystagon®. Mylan also becomes the #1 most dispensed line of pharmaceuticals in America—branded or generic.\*

Sadly, tragedy strikes Mylan when Chairman and Chief Executive Officer Roy McKnight dies suddenly of a heart attack. Within days, the Board of Directors announces that company President Mike Puskar will assume additional roles as Chairman and Chief Executive Officer.



- ◆ **1993:** Bertek, Inc., an innovator and manufacturer of state-of-the-art transdermal drug delivery systems, is acquired February 15.



- ◆ **1994:** Cidra, Puerto Rico, becomes the site of the company's third generic manufacturing facility with its opening in October.



- ◆ **1995:** Mylan becomes the most dispensed line of pharmaceuticals in America, branded or generic.\*



- ◆ **1996:** On February 28, Mylan acquires UDL Laboratories, Inc., the premier supplier of unit-dose multi-source pharmaceuticals to the institutional and long-term care marketplace.



- ◆ **1998:** On October 2, Mylan acquires Penederm Inc., which develops and markets patented topically administered prescription products using its proprietary delivery technology known as TopiCare™.

\* Data on file, Mylan Pharmaceuticals Inc.



MYLAN®

## The History of Mylan

### The 2000s

#### Into the New Millennium

As we look to the future, Mylan is strategically positioned for continued growth. Our company has both a generic division and branded division. Our staff has grown to more than 3,000 employees. Our manufacturing capacity has increased from less than 10,000 square feet to more than one million square feet. We have production facilities in three states and Puerto Rico. And our Bertek division dedicated its brand-new headquarters in Research Triangle Park, North Carolina.



By focusing on key principles of quality and integrity, Mylan has established a position of leadership in the pharmaceutical industry; in fact, today, Mylan is the #1 US-based manufacturer of generic pharmaceutical products.\* The company's success can be attributed to outstanding management, dedicated employees, and to upholding its founding corporate motto: "We either do it right or we don't do it at all."



- ◆ **2001:** Mylan celebrates its 40th birthday.



- ◆ **2002:** Mike Puskar steps down as Chief Executive Officer and assumes position of Chairman of the Board.



- ◆ **2002:** Robert Coury becomes Chief Executive Officer.



- ◆ **2002:** For the first time in company history, generic sales exceeded \$1 billion.†



- ◆ **2004:** Mylan is added to the S&P 500 list.

- ◆ **2005:** Mylan launches Fentanyl Transdermal System, its largest transdermal product launch to date.

\* IMS National Prescription Audit. December 2004.

† Data on file, Mylan Pharmaceuticals Inc.